BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 32277542)

  • 1. Aggressive morphologic variants of mantle cell lymphoma characterized with high genomic instability showing frequent chromothripsis, CDKN2A/B loss, and TP53 mutations: A multi-institutional study.
    Streich L; Sukhanova M; Lu X; Chen YH; Venkataraman G; Mathews S; Zhang S; Kelemen K; Segal J; Gao J; Gordon L; Chen Q; Behdad A
    Genes Chromosomes Cancer; 2020 Aug; 59(8):484-494. PubMed ID: 32277542
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Whole genome copy number analysis in search of new prognostic biomarkers in first line treatment of mantle cell lymphoma. A study by the LYSA group.
    Le Bris Y; Magrangeas F; Moreau A; Chiron D; Guérin-Charbonnel C; Theisen O; Pichon O; Canioni D; Burroni B; Maisonneuve H; Thieblemont C; Oberic L; Gyan E; Pellat-Deceunynck C; Hermine O; Delfau-Larue MH; Tessoulin B; Béné MC; Minvielle S; Le Gouill S
    Hematol Oncol; 2020 Oct; 38(4):446-455. PubMed ID: 32472610
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential effect of epigenetic alterations and genomic deletions of CDK inhibitors [p16(INK4a), p15(INK4b), p14(ARF)] in mantle cell lymphoma.
    Hutter G; Scheubner M; Zimmermann Y; Kalla J; Katzenberger T; Hübler K; Roth S; Hiddemann W; Ott G; Dreyling M
    Genes Chromosomes Cancer; 2006 Feb; 45(2):203-10. PubMed ID: 16258956
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TP53 mutations are common in mantle cell lymphoma, including the indolent leukemic non-nodal variant.
    Sakhdari A; Ok CY; Patel KP; Kanagal-Shamanna R; Yin CC; Zuo Z; Hu S; Routbort MJ; Luthra R; Medeiros LJ; Khoury JD; Loghavi S
    Ann Diagn Pathol; 2019 Aug; 41():38-42. PubMed ID: 31132650
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An Old Story Retold: Loss of G1 Control Defines A Distinct Genomic Subtype of Esophageal Squamous Cell Carcinoma.
    Wang Q; Bai J; Abliz A; Liu Y; Gong K; Li J; Shi W; Pan Y; Liu F; Lai S; Yang H; Lu C; Zhang L; Chen W; Xu R; Cai H; Ke Y; Zeng C
    Genomics Proteomics Bioinformatics; 2015 Aug; 13(4):258-70. PubMed ID: 26386145
    [TBL] [Abstract][Full Text] [Related]  

  • 6.
    Eskelund CW; Dahl C; Hansen JW; Westman M; Kolstad A; Pedersen LB; Montano-Almendras CP; Husby S; Freiburghaus C; Ek S; Pedersen A; Niemann C; Räty R; Brown P; Geisler CH; Andersen MK; Guldberg P; Jerkeman M; Grønbæk K
    Blood; 2017 Oct; 130(17):1903-1910. PubMed ID: 28819011
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mantle cell lymphomas with concomitant MYC and CCND1 breakpoints are recurrently TdT positive and frequently show high-grade pathological and genetic features.
    Aukema SM; Croci GA; Bens S; Oehl-Huber K; Wagener R; Ott G; Rosenwald A; Kluin PM; van den Berg E; Bosga-Bouwer AG; Hoogendoorn M; Hoster E; Bittmann I; Nagel I; Murga Penas EM; Kreuz M; Bausinger J; Belder W; Oschlies I; Dyer MJS; Jayne S; Siebert R; Klapper W
    Virchows Arch; 2021 Jul; 479(1):133-145. PubMed ID: 33528622
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TP53 mutation is frequent in mantle cell lymphoma with EZH2 expression and have dismal outcome when both are present.
    Kim DH; Siddiqui S; Jain P; Wang M; Thakral B; Li S; Miranda R; Vega F; Medeiros LJ; Ok CY
    Hum Pathol; 2024 Apr; 146():1-7. PubMed ID: 38460798
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mantle cell lymphoma-variant Richter syndrome: Detailed molecular-cytogenetic and backtracking analysis reveals slow evolution of a pre-MCL clone in parallel with CLL over several years.
    Klener P; Fronkova E; Berkova A; Jaksa R; Lhotska H; Forsterova K; Soukup J; Kulvait V; Vargova J; Fiser K; Prukova D; Alam M; Calvin Lenyeletse Maswabi B; Michalova K; Zemanova Z; Jancuskova T; Pekova S; Trneny M
    Int J Cancer; 2016 Nov; 139(10):2252-60. PubMed ID: 27407063
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The complex landscape of genetic alterations in mantle cell lymphoma.
    Royo C; Salaverria I; Hartmann EM; Rosenwald A; Campo E; Beà S
    Semin Cancer Biol; 2011 Nov; 21(5):322-34. PubMed ID: 21945515
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mantle-cell lymphoma genotypes identified with CGH to BAC microarrays define a leukemic subgroup of disease and predict patient outcome.
    Rubio-Moscardo F; Climent J; Siebert R; Piris MA; Martín-Subero JI; Nieländer I; Garcia-Conde J; Dyer MJ; Terol MJ; Pinkel D; Martinez-Climent JA
    Blood; 2005 Jun; 105(11):4445-54. PubMed ID: 15718413
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ATM and TP53 mutations show mutual exclusivity but distinct clinical impact in mantle cell lymphoma patients.
    Mareckova A; Malcikova J; Tom N; Pal K; Radova L; Salek D; Janikova A; Moulis M; Smardova J; Kren L; Mayer J; Trbusek M
    Leuk Lymphoma; 2019 Jun; 60(6):1420-1428. PubMed ID: 30626249
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genomic landscape and prognostic analysis of mantle cell lymphoma.
    Yang P; Zhang W; Wang J; Liu Y; An R; Jing H
    Cancer Gene Ther; 2018 Jun; 25(5-6):129-140. PubMed ID: 29755111
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NOTCH Signaling in Mantle Cell Lymphoma: Biological and Clinical Implications.
    Deshotels L; Safa FM; Saba NS
    Int J Mol Sci; 2023 Jun; 24(12):. PubMed ID: 37373427
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Complex analysis of the TP53 tumor suppressor in mantle cell and diffuse large B-cell lymphomas.
    Zlamalikova L; Moulis M; Ravcukova B; Liskova K; Malcikova J; Salek D; Jarkovsky J; Svitakova M; Hrabalkova R; Smarda J; Smardova J
    Oncol Rep; 2017 Oct; 38(4):2535-2542. PubMed ID: 28791403
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytogenetic findings in blastoid mantle cell lymphoma.
    Khoury JD; Sen F; Abruzzo LV; Hayes K; Glassman A; Medeiros LJ
    Hum Pathol; 2003 Oct; 34(10):1022-9. PubMed ID: 14608536
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Atypical fibroxanthoma and pleomorphic dermal sarcoma harbor frequent NOTCH1/2 and FAT1 mutations and similar DNA copy number alteration profiles.
    Griewank KG; Wiesner T; Murali R; Pischler C; Müller H; Koelsche C; Möller I; Franklin C; Cosgarea I; Sucker A; Schadendorf D; Schaller J; Horn S; Brenn T; Mentzel T
    Mod Pathol; 2018 Mar; 31(3):418-428. PubMed ID: 29099504
    [TBL] [Abstract][Full Text] [Related]  

  • 18. p53 and mdm2 in mantle cell lymphoma in leukemic phase.
    Solenthaler M; Matutes E; Brito-Babapulle V; Morilla R; Catovsky D
    Haematologica; 2002 Nov; 87(11):1141-50. PubMed ID: 12414343
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD5-negative blastoid variant mantle cell lymphoma: a diagnostic dilemma.
    Yamamoto N; Maeshima AM; Taniguchi H; Makita S; Fukuhara S; Munakata W; Suzuki T; Maruyama D; Izutsu K
    Hum Pathol; 2021 May; 111():84-91. PubMed ID: 33727166
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incidence and prognostic impact of secondary cytogenetic aberrations in a series of 145 patients with mantle cell lymphoma.
    Espinet B; Salaverria I; Beà S; Ruiz-Xivillé N; Balagué O; Salido M; Costa D; Carreras J; Rodríguez-Vicente AE; Luís García J; Hernández-Rivas JM; Calasanz MJ; Siebert R; Ferrer A; Salar A; Carrió A; Polo N; García-Marco JA; Domingo A; González-Barca E; Romagosa V; Marugán I; López-Guillermo A; Millá F; Luís Mate J; Luño E; Sanzo C; Collado R; Oliver I; Monzó S; Palacín A; González T; Sant F; Salinas R; Ardanaz MT; Font L; Escoda L; Florensa L; Serrano S; Campo E; Solé F
    Genes Chromosomes Cancer; 2010 May; 49(5):439-51. PubMed ID: 20143418
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.